Melatonin attenuates Her-2, p38 MAPK, p-AKT, and mTOR levels in ovarian carcinoma of ethanol-preferring rats

Journal of Cancer

Volumn 5, Issue 9, 2014, Pages 728-735

  Ferreira, Grazielle M ^a   Martinez, Marcelo ^b   Camargo, Isabel Cristina C ^a   Domeniconi, Raquel F ^a   Martinez, Francisco Eduardo ^a   de Almeida Chuffa, Luiz Gustavo ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO CARLOS   (Brazil)

Author keywords

Her 2; Melatonin; mTOR; Ovarian cancer; p AKT; p38 MAPK

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; ALCOHOL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; MAMMALIAN TARGET OF RAPAMYCIN; MELATONIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SESAME SEED OIL;

ALCOHOL CONSUMPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNOFLUORESCENCE TEST; NONHUMAN; OVARY; OVARY CARCINOMA; RAT; SHAM PROCEDURE; SIGNAL TRANSDUCTION;

EID: 84920926509     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.10196     Document Type: Article

References (36)

1. Cannistra SA. Cancer of the ovary. New Engl J Med. 2004; 351: 2519-65.
2. Fallows S, Price J, Atkinson RJ, et al. P53 mutation does not affect prognosis in ovarian epithelial malignancies. J Pathol. 2001; 194: 68-75.
3. Kelly MG, Alvero AB, Chen R, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006; 66: 3859-68.
4. Chen R, Alvero AB, Silasi DA, et al. Cancers take their Toll-the function and regulation of Toll-like receptors in cancer cells. Oncogene. 2008; 27: 225-33.
5. Sheng Q, Liu J. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. British J Cancer. 2011; 104: 1241-5.
6. Meric-Berstam F, Hung MC. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res. 2006; 12: 6326-30.
7. Reese DM, Slamon DJ. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells. 1997; 15: 1-8.
8. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009; 9: 463-475.
9. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005; 353: 1652-4.
10. Yang H-L, Lin K-Y, Juan Y-C, et al. The anti-cancer activity of Antrodia camphorata against human ovarian carcinoma (SKOV-3) cells via modulation of HER-2/neu signaling pathway. J Ethnopharmacol. 2013; 148: 254-65.
11. Srinivasan R, Poulsom R, Hurst HC, et al. Expression of the c-erb-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J Pathol. 1998; 185: 236-45.
12. Zeng T, Zhang CL, Song FY, et al. PI3K/AKT pathway activation was involved in acute ethanol-induced fatty liver in mice. Toxicology. 2012; 296: 56-66.
13. Corl AB, Berger KH, Ophir-Shohat G, et al. Happy hour, a Ste 20 family Kinase, implicates EGFR signaling in ethanol-induced behaviors. Cell. 2009; 137: 949-60.
14. Chuffa LG, Fioruci-Fontanelli BA, Mendes LO, et al. Characterization of chemically induced ovarian carcinomas in an ethanol-preferring rat model: influence of long-term melatonin treatment. Plos One. 2013; 8: e81676.
15. Stehle JH, Saade A, Rawashdeh O, et al. A survey of molecular details in the human pineal gland in the light of phylogeny, structure, function and chronobiological diseases. J Pineal Res. 2011; 51: 17-43.
16. Reiter RJ. Mechanisms of cancer inhibition by melatonin. J Pineal Res. 2004; 3: 213-4.
17. Wang J, Xiao X, Zhang Y, et al. Simultaneous modulation of COX-2, p 300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J Pineal Res. 2012; 53: 77-90.
18. Kimball SR, Abbas A, Jefferson LS. Melatonin represses oxidative stress-induced activation of the MAP kinase and mTOR signaling pathways in H4IIE hepatoma cells through inhibition of Ras. J Pineal Res. 2008; 44: 379-86.
19. Chuffa LG, Seiva FR, Fávaro WJ, et al. Melatonin and ethanol intake exert opposite effects on circulating estradiol and progesterone and differentially regulate sex steroid receptors in the ovaries, oviducts, and uteri of adult rats. Reprod Toxicol. 2013; 39: 40-9.
20. Chuffa LG, Seiva FR, Fávaro WJ, et al. Melatonin reduces LH, 17 beta- estradiol and induces differential regulation of sex steroid receptors in reproductive tissues during rat ovulation. Reprod Biol Endocrinol. 2011; 9: 108.
21. Chuffa LG, Amorim JP, Teixeira GR, et al. Long-term melatonin treatment reduces ovarian mass and enhances tissue antioxidant defenses during ovulation in the rat. Braz J Med Biol Res. 2011; 44: 217-23.
22. Hoyer PB, Davis JR, Bedrnicek JB, et al. Ovarian neoplasm development by 7,12-dimethylbenz[a]anthracene (DMBA) in a chemically-induced rat model of ovarian failure. Gynecol Oncol. 2009; 112: 610-5.
23. Tuefferd M, Couturier J, Penault-Llorca F, et al. Her2 status in ovarian carcinomas: A multicenter GINECO study of 320 patients. Plos One. 2007; 2: e1138.
24. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat rev mol cell biol. 2011; 2: 127-37.
25. Lanitis E, Dangaj D, Hagemann IS. Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. Plos one. 2012; 7: e49829.
26. Mao L, Yuan L, Slakey ML, et al. Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen- activated protein kinase signaling pathway. Breast Cancer Research. 2010; 12: R107.
27. Chazin V, Kaleko M, Miller A, et al. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene. 1992; 7: 1859-66.
28. Oh AS, Lorant LA, Holloway JN, et al. Hyperactivation of MAPK induces loss of ERa expression in breast cancer cells. Mol Endocrinol. 2001; 15: 1344-59.
29. Shin IS, Park JW, Shin NR, et al. Melatonin inhibits MUC5AC production via suppression of MAPK signaling in human airway epithelial cells. J Pineal Res. 2014; 56: 398-407.
30. Shi D, Xiao X, Wang J, et al. Melatonin suppresses proinflammatory mediators in lipopolysaccharide-stimulated CRL1999 cells via targeting MAPK, NF-?B, c/EBPß, and p300 signaling. J Pineal Res. 2012; 53: 154-65.
31. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009; 9: 463-75.
32. Ke Z, Lin H, Fan Z, et al. MMP-2 mediates ethanol-induced invasion of mammary epithelial cells over-expressing ErbB2. Int J Cancer. 2006; 119: 8-16.
33. Meng Q, Gao B, Goldberg ID, et al. Stimulation of cell invasion and migration by alcohol in breast cancer cells. Biochem Biophy Res Commun. 2000; 273: 448-53.
34. Jung JH, Sohn EJ, Shin EA, et al. Melatonin suppresses the expression of 45S preribosomal RNA and upstream binding factor and enhances the antitumor activity of puromycin in MDA-MB-231 breast cancer cells. Evid Based Complement Alternat Med. 2013; 2013: 879746.
35. Liu C, Jia Z, Zhang X, et al. Involvement of melatonin in autophagy- mediated mouse hepatoma H22 cell survival. Int Immunopharmacol. 2012; 12: 394-401.
36. Chuffa LG, Amorim JP, Teixeira GR, et al. Long-term exogenous melatonin treatment modulates overall feed efficiency and protects ovarian tissue against injuries caused by ethanol-induced oxidative stress in adult UChB rats. Alcohol Clin Exp Res. 2011; 35: 1498-508.